Heart : official journal of the British Cardiac Society
-
Randomized Controlled Trial Multicenter Study
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome.
In the Apixaban for Prevention of Acute Ischemic Events (APPRAISE-2) trial, the use of apixaban, when compared with placebo, in high-risk patients with a recent acute coronary syndrome (ACS) resulted in a significant increase in bleeding without a reduction in ischaemic events. The aim of this analysis was to provide further description of these bleeding events and to determine the baseline characteristics associated with bleeding in high-risk post-ACS patients. ⋯ NCT00831441.